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Twenty years of HIV research has yielded vast knowledge
about the immunological personality of HIV. Some of this
is promising. Serendipity coupled with good experiments
have taught us that seemingly antibodies of any specificity
may be able to eliminate HIV infectivity in vivo provided
such antibodies bind to virions with high enough avidity.
Can we induce such antibodies and do they under normal
conditions have to be focused on certain molecular com-
binations such as i.e. Gp120/CD4? Has the concept of
positive auto-immunity been truly analyzed in depth?
What is the present status of the concept of induction of
anti-toxin antibodies as a valuable component in an HIV
vaccine? Do new adjuvants provide possibilities for fur-
ther enhancing the capacity of T cell immunity in animal
model systems to prolong life? A suggested scheme to
reach "final" answers to some of these questions will be
discussed.
from 2006 International Meeting of The Institute of Human Virology
Baltimore, USA. 17–21 November, 2006
Published: 21 December 2006
Retrovirology 2006, 3(Suppl 1):S29 doi:10.1186/1742-4690-3-S1-S29
<supplement> <title> <p>2006 International Meeting of The Institute of Human Virology</p> </title> <note>Meeting abstracts. A single PDF containing all abstracts in this Supplement is available <a href=" http://www.biomedcentral.com/content/files/pdf/1742-4690-3-S1-full.pdf ">here</a></note> <url>http://www.biomedcentral.com/content/pdf/1742-4690-3-S1-info.pdf</url></supplement>
© 2006 Wigzell; licensee BioMed Central Ltd. 